On May 16, 2025, in New York, the FDA granted approval for the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, a significant development in combating Alzheimer's disease. This authorization signifies the first-ever blood test endorsed to assist in diagnosing Alzheimer's, representing a groundbreaking advancement and promising a new phase in the battle against the disease.